Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sharma, A.M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sharma, A.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Renal involvement in hypertensive cardiovascular disease

A.M. Sharma*

McMaster University, Hamilton, Ontario, Canada

* Arya M. Sharma, MD, Canada Research Chair for Cardiovascular Obesity Research & Management, McMaster University, Hamilton, Ontario, Canada

Abstract

Cardiovascular morbidity and mortality are elevated in renally impaired patients, especially if they are hypertensive. Diabetes is also associated with a high prevalence of cardiovascular morbidity and end-stage renal disease. Albuminuria, elevated serum creatinine, decreased creatinine clearance and proteinuria independently predict cardiovascular risk. Even patients with mild renal impairment should be treated to slow kidney disease progression and reduce vascular damage. Blood pressure control is effective in reducing vascular complications of diabetes, but not all classes of antihypertensive agents provide renoprotection. Angiotensin-converting enzyme inhibitors are superior to beta-blockers in preventing or delaying the loss of kidney function associated with hypertension. The renoprotection appears to be in part independent of the antihypertensive effect. Angiotensin II receptor blockers (ARBs) also reduce the risk of renal complications in diabetics. Telmisartan seems well suited to provide renoprotection because, unlike other ARBs, it is almost exclusively excreted by the liver and no initial dose adjustment is required for patients with mild-to-moderate renal impairment. Other advantages of telmisartan include its very high volume of distribution and long terminal elemination half-life. Clinical trials to evaluate telmisartan will address the problems of diabetes, renal impairment and end-organ disease.

Key Words: Angiotensin II receptor blockers • Nephropathy • Renin-angiotensin-aldosterone system • Renoprotection • Telmisartan

References

  1. US Renal Data System. USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Heath, National Institute of Diabetes and Digestive and Kidney Diseases; 2002.
  2. Ibrahim HA, Vora JP. Diabetic nephropathy. Baillieres Clin Endocrinol Metab. 1999;13:239–264[CrossRef]
  3. Gadsby R. Epidemiology of diabetes. Adv Drug Deliv Rev. 2002;54:1165–1172[CrossRef][Web of Science][Medline]
  4. 1998 US Renal Data System report. Incidence rate remains steady, improvements seen in survival. Nephrol News Issues. 1998;12:18–191998 US Renal Data System report. Incidence rate remains steady, improvements seen in survival. Nephrol News Issues. 1998;12:23
  5. US Renal Data System. USRDS 1998 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1998.
  6. Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498–1509[CrossRef][Web of Science][Medline]
  7. Jaradat MI, Molitoris BA. Cardiovascular disease in patients with chronic kidney disease. Semin Nephrol. 2002;22:459–473[Web of Science][Medline]
  8. Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996;11:1277–1285[Abstract/Free Full Text]
  9. Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int. 1996;49:1428–1434[Web of Science][Medline]
  10. Mogensen CE, Christensen CK. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356–360[Abstract]
  11. Andersen AR, Christiansen JS, Andersen JK, et al. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia. 1983;25:496–501[Web of Science][Medline]
  12. Klein R, Klein BE, Moss S, et al. Proteinuria in diabetes. Arch Intern Med. 1988;148:181–186[Abstract/Free Full Text]
  13. Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int. 2002;62:1402–1407[CrossRef][Web of Science][Medline]
  14. De Leeuw PW, thijs L, Birkenhager WH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the. J Am Soc Nephrol. 2002;13:2213–2222[Abstract/Free Full Text]
  15. Diercks GF, Hillege HL, van Boven AJ, et al. Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes. J Am Coll Cardiol. 2002;40:1401[Abstract/Free Full Text]
  16. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–210[Abstract/Free Full Text]
  17. Garg AX, Clark WF, Haynes RB, et al. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int. 2002;61:1486–1494[CrossRef][Web of Science][Medline]
  18. Landray MJ, Thambyrajah J, McGlynn FJ, et al. Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis. 2001;38:537–546[Web of Science][Medline]
  19. Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabet Med. 1988;5:126–134[Web of Science][Medline]
  20. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med. 2002;347:1256–1261[Free Full Text]
  21. Arima S, Ito S. New insights into actions of the renin-angiotensin system in the kidney: concentrating on the Ang II receptors and the newly described Ang-(1–7) and its receptor. Semin Nephrol. 2001;21:535–543[CrossRef][Web of Science][Medline]
  22. Leehey DJ, Singh AK, Alavi N, et al. Role of angiotensin II in diabetic nephropathy. Kidney Int. 2000;77:S93–S98 (suppl)
  23. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000;57:1803–1817[CrossRef][Web of Science][Medline]
  24. Bakris GL. Progression of diabetic nephropathy. A focus on arterial pressure level and methods of reduction. Diabetes Res Clin Pract. 1998;39:S35–S42 (suppl)
  25. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853[CrossRef][Web of Science][Medline]
  26. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713[Abstract/Free Full Text]
  27. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:421–429
  28. Wolf G, Butzmann U, Wenzel UO. The renin-angiotensin system and progression of renal dieases: from hemodynamics to cell biology. Nephron. 2003;93:P3–P13[CrossRef][Medline]
  29. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629–636[Abstract/Free Full Text]
  30. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–259[CrossRef][Web of Science][Medline]
  31. Perico N, Remuzzi G. Angiotensin II receptor antagonists and treatment of hypertension and renal disease. Curr Opin Nephrol Hypertens. 1998;7:571–578[Web of Science][Medline]
  32. Lewis EJ, Hunsicker LG, clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860[Abstract/Free Full Text]
  33. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869[Abstract/Free Full Text]
  34. Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Press. 2001;10(suppl 1):6–11[Web of Science][Medline]
  35. Stangier J, Schmid J, Türck D, et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C]-telmisartan in healthy volunteers. J Clin Pharmacol. 2000;40:1312–1322[Abstract]
  36. Hannedouche T, chanard J, Baumelou B, et al. Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst. 2001;2:246–254[Abstract/Free Full Text]
  37. Rippin J, Bain SC, Barnett AH. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study. J Diabetes Complications. 2002;16:195–200[CrossRef][Web of Science][Medline]
  38. Levey AS. Clinical practice. Nondiabetic kidney disease. N Engl J Med. 2002;347:1505–1511[Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sharma, A.M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sharma, A.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?